FEops HEARTguide vs Imbio PHA (4.0.0)
AI Verdict
Choose FEops HEARTguide if…
Choose FEops HEARTguide if you require advanced, patient-specific predictive simulations for complex structural heart procedure planning. This tool is ideal for cardiologists and cardiothoracic surgeons who need to optimize device sizing and positioning pre-operatively using digital twin technology to improve patient outcomes.
View FEops HEARTguide →Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if you need rapid, automated, and standardized measurements of cardiac structures from CT pulmonary angiogram (CTPA) scans. This software is best suited for radiologists and pulmonologists seeking to quickly assess right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension.
View Imbio PHA (4.0.0) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | FEops HEARTguide | Imbio PHA (4.0.0) |
|---|---|---|
| Deployment | Cloud Based platform | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Imbio PHA (4.0.0)Tool B emphasizes a 'fully-automated' and 'rapid' assessment, aiming for minimal user interaction with 'no user interfaces to learn' and results directly integrated into PACS as 'First-Read Ready'. While Tool A is described as intuitive and easy to use with significant time savings, its 'semi-automatic' and 'interactive' features suggest a more involved user experience.
Clinical Value
FEops HEARTguideTool A offers predictive simulations and digital twin technology to optimize device sizing and positioning for structural heart procedures, directly impacting patient outcomes. The PREDICT-LAA trial demonstrated significant improvements in procedural efficiency and outcomes, including a 40% more complete LAA occlusion and reduced complications. Tool B provides valuable diagnostic and risk stratification information for pulmonary embolism and hypertension, but Tool A's direct influence on procedural success and patient outcomes represents a higher clinical impact.
Pricing & Value
FEops HEARTguideBoth tools require direct contact for pricing, limiting transparency. However, Tool A has demonstrated significant clinical benefits, such as reduced procedural time, device usage, and complications, through the PREDICT-LAA trial. These efficiencies and improved patient outcomes strongly suggest a higher potential for cost savings and overall value, despite the formal cost-effectiveness remaining uncertain.
Enterprise Readiness
Imbio PHA (4.0.0)Tool B offers superior deployment flexibility, supporting cloud, enterprise (on-premise), or partner integrations, catering to diverse institutional IT and data governance needs. It explicitly provides an on-premise solution and is third-party HIPAA compliant certified. Tool A is cloud-based, HIPAA compliant, and FDA cleared, but lacks the explicit on-premise option.
Innovation
FEops HEARTguideTool A stands out with its 'AI and digital twin platform' for patient-specific predictive simulations in structural heart interventions, described as a unique and pioneering approach. Digital twin technology in cardiology is a rapidly evolving and cutting-edge field aimed at advancing precision medicine. Tool B's automated measurement of cardiac structures, while valuable, represents a more established application of AI in medical image processing.
Support & Docs
Imbio PHA (4.0.0)Tool B provides clear and comprehensive support, offering 24/7/365 phone and email assistance, an online case submission system, and readily available user manuals and product documentation upon request. Tool A's information on support and documentation is less explicit, with only mentions of 'training slide decks' and a general 'healthcare professionals' section.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | FEops HEARTguide | Imbio PHA (4.0.0) |
|---|---|---|
| Name | FEops HEARTguide | Imbio PHA (4.0.0) |
| Company | FEops NV | Imbio |
| Description | FEops HEARTguideu2122 is a cloud-based AI and digital twin platform for structural heart procedure planning, providing predictive simulations and anatomical measurements to optimize device sizing and positioning for improved patient outcomes. | Imbio PHA (4.0.0) is an FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. |
| Key Features | Predictive simulation technology, AI-based anatomical measurements, Digital twin technology for patient-specific replicas, Cloud-based platform with anytime, anywhere access, DICOM interface for CT scan upload, Semi-automatic identification and measurement of anatomical landmarks, Interactive 2D and 3D viewer, Evaluation of device sizing and positioning pre-operatively | Automated measurement of right and left ventricle diameters, Automated measurement of main pulmonary artery and aorta diameters, Calculates RV/LV and PA/Ao ratios, Utilizes artificial intelligence algorithms for anatomical identification and measurement, Generates annotated DICOM images, Provides summary reports in PDF format, Integrates with native DICOM tools and workflows, Rapid, fully-automated assessment (typically in minutes) |
| Specialties | Cardiology, Cardiothoracic Surgery | Cardiology, Pulmonology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring FEops HEARTguide and Imbio PHA (4.0.0).